PPARA inhibits inflammatory reactions, one of the key factors involved in atherosclerosis, by stopping NFκB signalling, positively regulating IκBα, inhibiting JUN function, negatively regulating COX2, etc [71]. The gene discussed is JUN; the disease is atherosclerosis.